02348 DAWNRAYS PHARMA
- 1.180
- -0.010-0.84%
DAWNRAYS PHARMA News
東瑞製葯：2023 年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Dongrui Pharmaceuticals (02348.HK) was granted an additional 60,000 shares of common stock by Li Qiling, worth approximately HK$70,200
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Li Qiling increased her common share holdings of $Dongrui Pharmaceuticals (02348.HK) by $60,000 at an average price of HK$1.17 per share on April 2, worth about HK$70,200. After increasing her holdings, Li Qiling's latest shareholding was 704 million shares, with a good position ratio of 46.94%. This transaction involves another related party: Xiong Rongli. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their shares in listed companies
Dongrui Pharmaceuticals (02348.HK) was granted an additional 20,000 shares of common stock by Li Qiling, worth approximately HK$23,200
On April 2, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 2, Li Qiling increased her common share holdings of $Dongrui Pharmaceuticals (02348.HK) by $20,000 at an average price of HK$1.16 per share on March 27, worth about HK$23,200. After increasing her holdings, Li Qiling's latest shareholding was 704 million shares, with a good position ratio of 46.94%. This transaction involves another related party: Xiong Rongli. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their listed companies
Dongrui Pharmaceuticals (02348.HK) received 76,000 additional shares of common stock by Li Qiling, worth approximately HK$88,200
On March 27, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 27, Li Qiling increased her common share holdings of $Dongrui Pharmaceuticals (02348.HK) by $76,000 at an average price of HK$1.16 per share on March 26, worth about HK$88,200. After increasing her holdings, Li Qiling's latest shareholding was 704 million shares, and the good position ratio increased from 46.93% to 46.94%. This transaction involves another related party: Xiong Rongli. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals holding 5% or more of the shares and
Dongrui Pharmaceuticals (02348.HK) obtained Xiong Rongli's additional common shares by 100,000 shares worth about HK$116,000
On March 27, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 27, Xiong Rongli increased his share share holdings of $100,000 of Dongrui Pharmaceuticals (02348.HK) with an average price of HK$1.16 per share on March 25, worth about HK$116,000. After the increase in holdings, Xiong Rongli's latest shareholding was 599 million shares, and the good position ratio increased from 39.89% to 39.90%. This transaction involves another related party: Li Qiling. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and public holding 5% or more of the shares
Dongrui Manufacturing (02348) will pay a final dividend of HK$0.065 per share on June 12
Dongrui Pharmaceuticals (02348) announced that it will be distributed on June 12, 2024 until December 3, 2023...
DAWNRAYS PHARMA To Go Ex-Dividend On May 28th, 2024 With 0.065 HKD Dividend Per Share
March 25th - $DAWNRAYS PHARMA(02348.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.065 HKD dividend per share on June 12th, 2024. The ex-div
Dawnrays' 2023 Profit Falls 9% on Lower Revenue
Dawnrays Pharmaceutical's (HKG:2348) attribrtuable profit fell 9% to 326 million yuan, or 0.2174 yuan per share, in 2023, from 358.1 million yuan, or 0.2389 yuan per share, in 2022, according to a Friday filing with the Hong Kong bourse.
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Changes in Hong Kong stocks | Dongrui Manufacturing (02348) fell by more than 10%. Profit attributable to shareholders of $326 million in 2023 decreased by 8.95% year-on-year
Dongrui Manufacturing (02348) fell by more than 10%, down 12.88% at press time, to HK$1.15, with a turnover of HK$1.54 million.
Dongrui Pharmaceuticals (02348) will pay a final dividend of HK6.5 cents per share on June 12
Dongrui Pharmaceuticals (02348) announced that it will pay a final dividend of HK6.5 cents per share on June 12, 2024.
The annual profit attributable to owners of Dongrui Pharmaceuticals (02348.HK) was about 326 million yuan, a year-on-year decrease of about 9.0%
Gelonghui, March 22丨Dongrui Pharmaceutical (02348.HK) announced that for the year ended December 31, 2023, the company recorded revenue of about RMB 1.15 billion, a year-on-year decrease of about 9.9%. Profit attributable to owners of parent companies was approximately RMB 326 million, a year-on-year decrease of approximately 9.0%. The Board recommended a year-end dividend of HK$0.065 per share.
DAWNRAYS PHARMA: ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”
Analysis
Price Target
No Data
